Cargando…
Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy
BACKGROUND: Metachromatic leukodystrophy (MLD), a relentlessly progressive and ultimately fatal condition, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A (ARSA). Historically management has been palliative or supportive care. Hematopoiet...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531467/ https://www.ncbi.nlm.nih.gov/pubmed/36195888 http://dx.doi.org/10.1186/s13023-022-02518-z |
_version_ | 1784801908575174656 |
---|---|
author | Eichler, F. Sevin, Caroline Barth, M. Pang, F. Howie, K. Walz, M. Wilds, A. Calcagni, C. Chanson, C. Campbell, L. |
author_facet | Eichler, F. Sevin, Caroline Barth, M. Pang, F. Howie, K. Walz, M. Wilds, A. Calcagni, C. Chanson, C. Campbell, L. |
author_sort | Eichler, F. |
collection | PubMed |
description | BACKGROUND: Metachromatic leukodystrophy (MLD), a relentlessly progressive and ultimately fatal condition, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A (ARSA). Historically management has been palliative or supportive care. Hematopoietic stem cell transplantation is poorly effective in early-onset MLD and benefit in late-onset MLD remains controversial. Hematopoietic stem cell gene therapy, Libmeldy (atidarsagene autotemcel), was recently approved by the European Medicines Agency for early-onset MLD. Treatment benefit is mainly observed at an early disease stage, indicating the need for early diagnosis and intervention. This study contributes insights into the caregiver language used to describe initial MLD symptomatology, and thereby aims to improve communication between clinicians and families impacted by this condition and promote a faster path to diagnosis. RESULTS: Data was collected through a moderator-assisted online 60-min survey and 30-min semi-structured follow-up telephone interview with 31 MLD caregivers in the United States (n = 10), France (n = 10), the United Kingdom (n = 5), and Germany (n = 6). All respondents were primary caregivers of a person with late infantile (n = 20), juvenile (n = 11) or borderline late infantile/juvenile (n = 1) MLD (one caregiver reported for 2 children leading to a sample of 32 individuals with MLD). Caregivers were asked questions related to their child’s initial signs and symptoms, time to diagnosis and interactions with healthcare providers. These results highlight the caregiver language used to describe the most common initial symptoms of MLD and provide added context to help elevate the index of suspicion of disease. Distinctions between caregiver descriptions of late infantile and juvenile MLD in symptom onset and disease course were also identified. CONCLUSIONS: This study captures the caregiver description of the physical, behavioral, and cognitive signs of MLD prior to diagnosis. The understanding of the caregiver language at symptom onset sheds light on a critical window of often missed opportunity for earlier diagnosis and therapeutic intervention in MLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-022-02518-z. |
format | Online Article Text |
id | pubmed-9531467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95314672022-10-05 Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy Eichler, F. Sevin, Caroline Barth, M. Pang, F. Howie, K. Walz, M. Wilds, A. Calcagni, C. Chanson, C. Campbell, L. Orphanet J Rare Dis Research BACKGROUND: Metachromatic leukodystrophy (MLD), a relentlessly progressive and ultimately fatal condition, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the enzyme arylsulfatase A (ARSA). Historically management has been palliative or supportive care. Hematopoietic stem cell transplantation is poorly effective in early-onset MLD and benefit in late-onset MLD remains controversial. Hematopoietic stem cell gene therapy, Libmeldy (atidarsagene autotemcel), was recently approved by the European Medicines Agency for early-onset MLD. Treatment benefit is mainly observed at an early disease stage, indicating the need for early diagnosis and intervention. This study contributes insights into the caregiver language used to describe initial MLD symptomatology, and thereby aims to improve communication between clinicians and families impacted by this condition and promote a faster path to diagnosis. RESULTS: Data was collected through a moderator-assisted online 60-min survey and 30-min semi-structured follow-up telephone interview with 31 MLD caregivers in the United States (n = 10), France (n = 10), the United Kingdom (n = 5), and Germany (n = 6). All respondents were primary caregivers of a person with late infantile (n = 20), juvenile (n = 11) or borderline late infantile/juvenile (n = 1) MLD (one caregiver reported for 2 children leading to a sample of 32 individuals with MLD). Caregivers were asked questions related to their child’s initial signs and symptoms, time to diagnosis and interactions with healthcare providers. These results highlight the caregiver language used to describe the most common initial symptoms of MLD and provide added context to help elevate the index of suspicion of disease. Distinctions between caregiver descriptions of late infantile and juvenile MLD in symptom onset and disease course were also identified. CONCLUSIONS: This study captures the caregiver description of the physical, behavioral, and cognitive signs of MLD prior to diagnosis. The understanding of the caregiver language at symptom onset sheds light on a critical window of often missed opportunity for earlier diagnosis and therapeutic intervention in MLD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13023-022-02518-z. BioMed Central 2022-10-04 /pmc/articles/PMC9531467/ /pubmed/36195888 http://dx.doi.org/10.1186/s13023-022-02518-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Eichler, F. Sevin, Caroline Barth, M. Pang, F. Howie, K. Walz, M. Wilds, A. Calcagni, C. Chanson, C. Campbell, L. Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy |
title | Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy |
title_full | Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy |
title_fullStr | Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy |
title_full_unstemmed | Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy |
title_short | Understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy |
title_sort | understanding caregiver descriptions of initial signs and symptoms to improve diagnosis of metachromatic leukodystrophy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531467/ https://www.ncbi.nlm.nih.gov/pubmed/36195888 http://dx.doi.org/10.1186/s13023-022-02518-z |
work_keys_str_mv | AT eichlerf understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT sevincaroline understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT barthm understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT pangf understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT howiek understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT walzm understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT wildsa understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT calcagnic understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT chansonc understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy AT campbelll understandingcaregiverdescriptionsofinitialsignsandsymptomstoimprovediagnosisofmetachromaticleukodystrophy |